Virginia Cancer Specialists | Association Partnerships

Alex Spira, MD, PhD, discusses a subset analysis of the phase 3 MARIPOSA trial looking at dose interruptions during the course of amivantamab and lazertinib treatment for EGFR-mutant non-small cell lung cancer.

According to a subset analysis of the phase 3 MARIPOSA trial, dose interruptions during the course of amivantamab and lazertinib treatment were still effective in EGFR-mutant non-small cell lung cancer.

In an interview with Targeted Oncology, Geoffrey D. Moorer, MD, discussed recent trending topics in the field of oncology among hospital tumor boards and committees.

Dipti Patel-Donnelly, MD, highlights challenges for physicians and patients when managing treatment of hematologic malignancies in the community setting.

In an interview with Targeted Oncology, Muhammad Siddiqui, MD, explained the role that palliative medicine plays in a cancer treatment plan and how oncologists and palliative care physicians can work together in patients’ best interests.

Dipti Patel-Donnelly, MD, discusses the gaps between academic centers and community oncology regarding treatments for hematologic malignancies.

Mohamad Adham Salkeni, MD, FRCPC, discusses the mechanism of action of ivaltinostat and what rationalizes its use in combination with capecitabine for patients with metastatic pancreatic adenocarcinoma.

In an interview, Mohamad Adham Salkeni, MD, FRCPC, discussed the ongoing study of maintenance ivaltinostat plus capecitabine or capecitabine monotherapy in patients with metastatic pancreatic adenocarcinoma whose disease has not progressed on first-line FOLFIRINOX.

Treatment has been initiated in a phase 1/2 study of TNG260 added to pembrolizumab in patients with advanced or metastatic solid tumors.

In an interview with Targeted Oncology, Mitul Gandhi, MD, reviewed the latest guideline recommendations for the workup and treatment of acute myeloid leukemia.

With statistically significant and clinically meaningful event-free survival improvement in patients with stage II-IIIB Non–small cell lung cancer, could perioperative pembrolizumab in combination with chemotherapy become a new treatment option?

KRYSTAL-1 results led the FDA to accelerate the approval of adagrasib for KRAS G12C-mutated locally advanced or metastatic non–small cell lung cancer.

A highly anticipated presentation at the 2022 World Conference on Lung Cancer will be the first report of efficacy and safety from the phase 1b/2 CodeBreak 101 clinical trial and will provide updated results from the phase 2 CodeBreak 100 study.

Treatment with the KRAS G12C inhibitor adagrasib showed a promising objective response rate and disease control rate in patients with previously treated KRAS G12C–mutated non–small cell lung cancer.

Alexander Spira, MD, PhD, FACP, director of the Virginia Cancer Specialists Research Institute, discusses the current standard of care for EGFR exon 20 insertion-mutated lung cancer.

Alexander Spira, MD, PhD, FACP, director of the Virginia Cancer Specialists Research Institute, discusses the safety profile of amivantamab and lazertinib in EGFR-mutated non-small cell lung cancer, based on data from the CHRYSALIS tria.

Targeted Oncology™ is excited to announce it has expanded its Strategic Alliance Partnership program with the addition of the Kentucky Society of Clinical Oncology and Virginia Cancer Specialists, strengthening its position in the oncology space.